TY - JOUR
T1 - Prioritising the most needed paediatric antiretroviral formulations
T2 - the PADO4 list
AU - PADO4 participants
AU - Penazzato, Martina
AU - Townsend, Claire L.
AU - Rakhmanina, Natella
AU - Cheng, Yao
AU - Archary, Moherndran
AU - Cressey, Timothy R.
AU - Kim, Maria H.
AU - Musiime, Victor
AU - Turkova, Anna
AU - Ruel, Theodore D.
AU - Rabie, Helena
AU - Sugandhi, Nandita
AU - Rojo, Pablo
AU - Doherty, Meg
AU - Abrams, Elaine J.
AU - Abrams, Elaine
AU - Ananworanich, Jintanat
AU - Andrieux-Meyer, Isabelle
AU - Belew, Yodit
AU - Best, Brookie
AU - Bologna, Rosa
AU - Burry, Jessica
AU - Carpenter, Deborah
AU - Clayden, Polly
AU - Colbers, Angela
AU - Conway, Magda
AU - Dangarembizi, Mutsa
AU - Essajee, Shaffiq
AU - Gonzalez Tome, Maribel
AU - Hill, Andrew
AU - Khoo, Saye
AU - Kim, Maria
AU - Lewis, Linda
AU - Lee, Janice
AU - Lockman, Shahin
AU - Mahaka, Imelda
AU - Mirochnick, Mark H.
AU - Mofenson, Lynne
AU - Muhimpundu, Mireille
AU - Mushavi, Angela
AU - Obimbo, Elizabeth
AU - Pascual, Fernando
AU - Perez Casas, Carmen
AU - Pozniak, Anton
AU - Ruel, Theodore
AU - Schapiro, Jonathan
AU - Siberry, George
AU - Simione, Teresa Beatriz
AU - Tidiane Tall, Cheick
AU - Venter, Francois
N1 - Publisher Copyright:
© 2019 Elsevier Ltd
PY - 2019/9
Y1 - 2019/9
N2 - Despite considerable progress in paediatric HIV treatment and timely revision of global policies recommending the use of more effective and tolerable antiretroviral regimens, optimal antiretroviral formulations for infants, children, and adolescents remain limited. The Paediatric Antiretroviral Drug Optimization group reviews medium-term and long-term priorities for antiretroviral drug development to guide industry and other stakeholders on formulations most needed for low-income and middle-income countries. The group convened in December, 2018, to assess progress since the previous meeting and update the list of priority formulations. Issues relating to drug optimisation for neonatal prophylaxis and paediatric treatment, and those relating to the investigation of novel antiretrovirals in adolescents and pregnant and lactating women were also discussed. Continued focus on identifying, prioritising, and providing access to optimal antiretroviral formulations suitable for infants, children, and adolescents is key to ensuring that global HIV treatment targets can be met.
AB - Despite considerable progress in paediatric HIV treatment and timely revision of global policies recommending the use of more effective and tolerable antiretroviral regimens, optimal antiretroviral formulations for infants, children, and adolescents remain limited. The Paediatric Antiretroviral Drug Optimization group reviews medium-term and long-term priorities for antiretroviral drug development to guide industry and other stakeholders on formulations most needed for low-income and middle-income countries. The group convened in December, 2018, to assess progress since the previous meeting and update the list of priority formulations. Issues relating to drug optimisation for neonatal prophylaxis and paediatric treatment, and those relating to the investigation of novel antiretrovirals in adolescents and pregnant and lactating women were also discussed. Continued focus on identifying, prioritising, and providing access to optimal antiretroviral formulations suitable for infants, children, and adolescents is key to ensuring that global HIV treatment targets can be met.
UR - http://www.scopus.com/inward/record.url?scp=85071639026&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071639026&partnerID=8YFLogxK
U2 - 10.1016/S2352-3018(19)30193-6
DO - 10.1016/S2352-3018(19)30193-6
M3 - Review article
C2 - 31498110
AN - SCOPUS:85071639026
SN - 2352-3018
VL - 6
SP - e623-e631
JO - The Lancet HIV
JF - The Lancet HIV
IS - 9
ER -
